Our study is the first to report the potential of brazilin from Caesalpinia sappan herb as a natural compound for the development of novel PCSK9 inhibitor, which could lead to new hypercholesterolemia drugs by disrupting the interaction between PCSK9 and LDLR. Here, PCSK9 is linked to familial hypercholesterolemia.